Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
thyroid eye disease
Biotech
Yarrow blooms with $1.37B autoimmune thyroid disease deal
Through a deal worth up to $1.37 billion, New York-based Yarrow gains ex-China rights to a potential first-in-class antibody targeting TSHR.
Angus Liu
Dec 16, 2025 11:00am
Kissei pays Viridian $70M to challenge Amgen for Japanese market
Jul 30, 2025 4:50am
Acelyrin to be absorbed into Alumis in all-stock merger
Feb 7, 2025 5:35am
Sling's oral Tepezza rival hits goal in thyroid eye disease
Jan 14, 2025 8:16am
China-based biotech plans ph. 3 after seeing midstage eye data
Oct 22, 2024 10:37am
Viridian eye disease phase 3 hits, advancing push to rival Amgen
Sep 10, 2024 8:10am
